Last reviewed · How we verify

NCT05396417

How Well do the Current Cesarean Deliveries Adhere to the Published ERAS Guidelines?

Status unknown Last updated 26 April 2023
What this trial tests

trial testing cesarean delivery in Cesarean Section Complications in 500 participants. Status unknown.

Timeline
1 January 2023
Primary endpoint
31 July 2023
31 July 2023

Quick facts

Lead sponsorWomen's Hospital HUS
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment500
Start date1 January 2023
Primary completion31 July 2023
Estimated completion31 July 2023
Sites1 location across Finland

Drugs / interventions tested

Conditions studied

Sponsor

Women's Hospital HUS

Who can join

Adults 18 to 55, female only, with Cesarean Section Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Local guidelines for the postoperative care of women who have undergone cesarean delivery at the HUS/Women's hospital are based recommendations by the ERAS society. This study will take a prospective sample of 500 parturients who have gone through a cesarean delivery and their care will be verified against the local check-list for cesarean delivery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of cesarean delivery

Trials testing the same drug.

Other recruiting trials for Cesarean Section Complications

Currently open trials in the same condition.

Other Women's Hospital HUS trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05396417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing